ProBioGen licenses GlymaxX tech to Sanofi
Berlin-based ProBioGen AG has signed a commercial multi-product license agreement with Sanofi. Under the agreement, Sanofi will integrate ProBioGen’s proprietary GlymaxX technology into their product development strategy for an undisclosed number of antibody candidates across several business units. GlymaxX enables a boost of antibody-dependent cell-mediated cytotoxicity (ADCC), consequently leading to an elevated NK cell mediated […]